16 March 2026
TRPC4 and TRPC5 are members of the transient receptor potential canonical (TRPC) family of non‑selective cation channels that form tetrameric complexes permeable to calcium and sodium. These channels are widely expressed in brain regions such as the amygdala and prefrontal cortex, which are considered to play central roles in emotional regulation. Activation of TRPC4/5 via G‑protein‑coupled receptor signaling induces sustained calcium entry and increases neuronal excitability. Beyond the central nervous system, TRPC4/5 are also expressed in peripheral tissues, including the cardiovascular system, where they contribute to the regulation of vascular tone and cardiac physiology.
To advance research on TRPC4/5 biology beyond neurological dysfunctions and disease, we are offering HC‑070, a potent and highly selective inhibitor of TRPC4 and TRPC5, free of charge. Researchers will retain full ownership of their data, and we encourage publication of resulting findings to further strengthen the growing body of knowledge in this field.
No registration required
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About HC-070:
HC‑070 is a potent dual TRPC4/TRPC5 channel inhibitor (in vitro IC50 ≤ 0.5 nM) with low MDCK efflux ratio and favorable oral bioavailability in mice. It exhibits high target specificity, not inhibiting any of 44 tested targets at 10 µM concentration. Preclinically, HC‑070 reduces calcium influx and thereby helps restore balanced neuronal activity in rodent models. Its well‑defined pharmacological profile makes HC‑070 an excellent tool compound for investigating TRPC4/5 biology in vitro as well as in vivo.
About opnMe:
opnMe.com, the open innovation portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. As part of our “Molecules to Order” pillar, we share well-characterized tool compounds free of charge with no IP strings attached. With “opn2EXPERTS”, we enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our opn2TALENTS PostDoc grants provide an opportunity for high-caliber talents to pitch their scientific approaches for well-defined research questions to conduct their research at one of our discovery research sites.